SecBot SecBot
8-K ·Filed Aug 24, 2026

ANIP

ANI PHARMACEUTICALS INC
NEUTRAL
Impact 2/10
Horizonimmediate Processed2mo ago SEC0001023024-26-000071
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

This is a routine board appointment and resignation with no immediate trading implications. Monitor for any future business development announcements that may follow from Gosebruch's strategic expertise.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$74.17
T+0 close · Aug 24, 2026 · via day close
Latest settled
−5.64%
T+60 · $69.99
Vs SPY
−1.57%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 24 $74.17entry
  2. T+1 · 3mo ago +2.00%α +1.68% · $75.65
  3. T+5 · 3mo ago −1.24%α −1.71% · $73.25
  4. T+20 · 2mo ago +5.04%α +3.73% · $77.91
  5. T+60 · 5d ago −5.64%α −1.57% · $69.99
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ANI Pharmaceuticals appointed Henry Gosebruch to its Board of Directors effective August 19, 2026, and announced the resignation of director Muthusamy Shanmugam, who remains in his executive management role. The board changes are routine and carry no material financial impact on the company's operations or outlook.

Key Facts

  • Henry Gosebruch appointed to the Board of Directors effective August 19, 2026
  • Muthusamy Shanmugam resigned as director effective August 23, 2026, but remains Head of R&D and COO of NJ Operations
  • Gosebruch receives an initial restricted stock award with a grant date fair value of $525,000, vesting over three years
  • Gosebruch brings over 30 years of biopharma strategy and M&A experience, including former EVP and Chief Strategy Officer at AbbVie

Financial Impact

No material financial impact. Director compensation includes a $525,000 initial restricted stock award.

Risk Factors

  • No material risks identified from this filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001023024-26-000071
Document: 0001023024-26-000071-index.html0001023024-26-000071
Document: 0001023024-26-000071.txt0001023024-26-000071

Track record

34 reports on ANIP

Performance horizon

4 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +8.88% at T+60 after the Apr 8, 2026 report. 8 of 12 went positive at some point.

Filters
  1. Nov 18, 20263d ago Insider Cluster Neutral 2/10 Entry $69.13 Now $68.55 −0.84% settles Dec 18
  2. Nov 16, 20265d ago 144 Neutral 2/10 Entry $69.99 Now $68.55 −2.06% settles Dec 16
  3. Nov 16, 20266d ago 8-K Neutral 3/10 Entry $70.89 Now $68.55 −3.30% settles Dec 15
  4. Nov 9, 202612d ago Institutional Cluster Mixed 3/10 Entry $67.79 Now $68.55 +1.12% settles Dec 8
  5. Nov 5, 202616d ago 8-K Neutral 5/10 Entry $67.41 Now $68.55 +1.69% settles Dec 7
  6. Nov 5, 202617d ago 8-K Bullish 6/10 No price data
  7. Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
  8. Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
  9. Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
  10. Oct 29, 202623d ago 144 Neutral 2/10 Entry $72.00 Now $68.55 −4.79% settles Nov 30
Showing 10 of 34

US Market Status

Market Closed · Opens Mon (25h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 24, 2026